item management s discussion and analysis of financial condition and results of operations 
overview the statements contained in this report  if not historical  are forward looking statements within the meaning of the private securities litigation reform act of  and involve risks and uncertainties that could cause actual results to differ materially from the financial results described in such forward looking statements 
these risks and uncertainties include  among others  whether the company will receive regulatory approval to market any products besides the atrisorb r gtr barrier product  the results of current and future clinical trials  the time  costs and expenses associated with the regulatory approval process for products 
the success of the company s business operations is in turn dependent on factors such as the effectiveness of the company s marketing strategies to market its current and any future products  the company s ability to manufacture products on a commercial scale  the appeal of the company s mix of products  the company s success at entering into and collaborating with others to conduct effective strategic alliances and joint ventures  general competitive conditions within the biotechnology and drug delivery industry and general economic conditions 
further  any forward looking statement or statements speak only as of the date on which such statement or statements were made  and the company undertakes no obligation to update any forward looking statement or statements to reflect events or circumstances after the date on which such statement or statements were made 
since its inception  the company has devoted its efforts and resources primarily to the research and development of periodontal products 
prior to  the company s revenues have been derived from interest income and payments from unaffiliated third parties for contract research 
in march   the company received clearance from the fda to market its first dental product  the atrisorb r gtr barrier 
shortly thereafter  the company commenced sales of the atrisorb r gtr barrier in the united states and certain european countries and began recording sales revenues 
results of operations year ended december  compared to year ended december  total revenue for the year ended december   was approximately  compared to approximately  for the year ended december   representing an increase 
the increase in total revenue was primarily due to increases in sales  contract revenue and interest income 
the company had sales of approximately  during the year ended december   primarily representing sales of the atrisorb r gtr barrier during the company had no product sales during contract revenue was approximately  for the year ended december   compared to approximately  for the year ended december   representing a increase 
contract revenue represents revenue the company received from grants and from unaffiliated third parties for performing contract research and development activities utilizing the atrigel r drug delivery system 
the increased revenues are primarily due to the company being awarded two federal research grants during the current year 
interest income for the year ended december   was approximately  compared to approximately  for the year ended december   representing a increase 
the increase in interest income was due to an increase in principal investments during as a result of the receipt of approximately  in proceeds from the company s common stock offering completed in may cost of goods sold were  for the year ended december  were primarily associated with the launch of the company s first dental product  the atrisorb r gtr barrier product in the united states and certain european countries 
the company did not record cost of goods sold for the year ended december  research and development atridox tm product expenses for the year ended december   were approximately  compared to approximately  for the year ended december   representing a decrease due to the completion of phase clinical trials on atridox tm in may research and development other expenses  which included activities for the atrisorb r gtr barrier product and other research activities for the year ended december   were approximately  for the year ended december  compared to approximately  for the year ended december   representing a increase 
the increase was primarily a result of hiring additional personnel in the manufacturing and quality assurance quality control departments  and expenses related to federal grants received in administrative and marketing expenses were approximately  for the year ended december   compared to  for the year ended december   representing a increase 
the primary reasons for this increase were expenses related to the initiation of marketing and sales efforts related to the atrisorb r gtr barrier product 
this expense is expected to decrease in future years with the signing of the block agreement 
during  the company recorded a one time non cash charge of approximately  for compensation expense associated with the cancellation of certain employee incentive stock options with a five year term and the issuance of new non qualified stock options which extended the term to ten years 
the company recorded a net loss of approximately  for the year ended december   compared to a net loss of  for the year ended december   representing a decrease 
however  exclusive of a one time charge of approximately  associated with the acquisition of vipont royalty income fund  ltd 
the acquisition  the prior year loss would be approximately  therefore  the loss for the year ended december  actually represents a increase over the year ended december  the increased loss was primarily due to expenses associated with the commencement of marketing and manufacturing activities related to the atrisorb r gtr barrier product 
year ended december  compared to year ended december  contract revenue represented revenue the company received from grants and from unaffiliated third parties for performing contract research and development activities for the atrigel r drug delivery system  and was approximately  for the year ended december   compared to approximately  for the year ended december  the decrease in contract revenue was a result of the company completing a number of contracts that were in progress in the comparable period  while contracts initiated in the period ended december  generated less revenue 
interest income for the year ended december   was approximately  compared to approximately  for the year ended december  interest income decreased due to a reduction in principal balances of investments as a result of the funds being used in general operations 
the majority of the funds were invested in us government bond funds  long term us government and government agency investments 
the remaining cash and cash equivalents were invested in interest bearing accounts to fund the company s short term operations 
a loss on sale of marketable securities for the year ended december   was approximately  compared to a loss of approximately  for the year ended december  the loss for the year ended december  was substantially less than the comparable period due to improved market conditions at the time at which the securities were sold 
the prior period loss resulted from the sale of securities  available for sale at a time when the bond market had substantially declined compared to the period when the securities were purchased 
the proceeds from the sale of marketable securities were used to fund normal operations 
research and development atridox tm product expenses for the year ended december   were approximately  compared to approximately  for the year ended december  the increase was significant and resulted from the continuation of two phase clinical trials which began in january administrative and marketing expenses increased to approximately  during the year ended december   from approximately  for the year ended december  the increase resulted primarily from expenses associated with efforts to obtain a corporate marketing partner  legal fees and expenses associated with the recruitment and hiring of new employees 
acquisition of rights for approximately  for the year ended december  represented i the issuance of  shares of common stock valued at approximately per share in the acquisition and ii approximately  in expenses related to the acquisition 
the company recorded a net loss of approximately  for the year ended december   compared to a net loss of approximately  for the year ended december  the loss for the year ended december  was higher primarily due to a one time charge of  associated with the acquisition 
the current period loss was further increased due to decreased revenues from research contracts  increased expenses associated with the continuation of two  phase clinical trials for the atridox tm product  and additional research and development on the atrisorb r gtr barrier and the atrigel r drug delivery system 
liquidity and capital resources as of december   the company had cash and cash equivalents of approximately  marketable securities available for sale of approximately   in restricted cash  and other current assets of approximately  for total current assets of approximately  current liabilities were approximately  which resulted in working capital of approximately  restricted cash represents  received by the company from block as a payment under the block agreement for the sale of marketing rights to the atrisorb r gtr barrier  which was placed in escrow until february  accordingly  the company deferred recognition of the revenue until  and the  payment is included in restricted cash equivalents as of december  during the year ended december   the company used net cash from operating activities of approximately  this was primarily a result of a net loss of approximately  net cash provided by investing activities was approximately  during the year ended december  the principal reason for the increase was from the sale of marketable securities and the proceeds from maturities of marketable securities to fund normal operating activities reduced by the acquisitions of property  plant and equipment 
net cash provided by financing activities was approximately  from the issuance and sale of  shares of common stock which was completed in may the company s long term capital expenditure requirements will depend on numerous factors  including the progress of the company s research and development programs  the time required to file and process regulatory approval applications  the development of the company s commercial manufacturing facilities  the ability of the company to obtain additional licensing arrangements  and the demand for the company s products  if and when approved 
the company expended approximately  for property  plant and equipment and leasehold improvements and approximately  for patent development in the year ended december  compared to  and  respectively  for the year ended december  the increase is a result of the purchase of the new manufacturing facility and equipment during the company expects to continue to incur substantial expenditures for research and development  testing  regulatory compliance and to hire additional management  scientific  manufacturing and administrative personnel 
the company will also continue to expend a significant amount of funds in its ongoing clinical studies 
these expenses will be partially offset by a decrease in sales and marketing expenses as a result of the block agreement and potential fees and royalties 
further  the company expects to continue to incur substantial operating losses for the foreseeable future 
depending on the results of the company s research and development activities  the company may determine to accelerate or expand its efforts in one or more of its proposed areas and may therefore require additional funds earlier than presently anticipated 
management believes that under the current operating plan its existing capital resources will be sufficient to meet its operating expenses and capital expenditure requirements for the foreseeable future 
management currently has no commitments for raising additional capital 
the company s long term success depends on sales of products that must undergo an extensive regulatory approval process 
there can be no assurance that regulatory agency approvals will be obtained for any products or drugs developed or discovered by the company  or that the company will be successful in developing any products or drugs 

